There will be little Labor Day relaxing in parts of Bayer AG, as the company says it will be working through the three-day weekend to get its just-approved long-acting recombinant Factor VIII replacement hemophilia A product Jivi (BAY94-9027) ready to ship in the US.
Bayer To Ship Long-Acting Hemophilia Infusion Jivi In A Jiffy
The company believes there is room in the market for its more standard-acting hemophilia A products Kogenate and Kovaltry, as well as a long half-life product like Jivi.
